Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2021

18.06.2021 | original report

Value of autophagy-related gene 5 (ATG5) expression as a prognostic marker in adults with newly diagnosed acute lymphoblastic leukaemia (ALL)

verfasst von: Rasha I. Ibrahim, Haydi S. Mohamed, Mary G. Nagib, Hebatullah M. Fares, Alia M. Saeed

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Background

Autophagy is considered a pivotal cellular mechanism to cope with stress and maintain homeostasis. It is frequently dysregulated in various types of cancers with some exhibiting excessive and others having reduced autophagy levels.

Aim

The goal was to determine autophagy status in newly diagnosed adult acute lymphoblastic leukaemia (ALL) patients compared to age- and sex-matched controls. Moreover, its prognostic impact on disease characteristics and response to treatment were evaluated.

Patients and methods

Thirty-five newly diagnosed adult ALL patients were recruited and age and sex matched to 15 healthy control subjects. ATG5 expression was measured on diagnosis using real-time quantitative polymerase chain reaction (qPCR). Cases have been followed up for one year after enrolment into the study.

Results

Mean ATG5 expression in ALL was twice that of controls, which is a high statistically significant difference (2.15 ± 2.2 vs 1.09 ± 0.47, P value = 0.01). High ATG5 expression has been significantly associated with B‑ALL phenotype, lower haemoglobin and lower platelet counts. Of note, the higher expressor group had higher bone marrow and peripheral blood blast percentages and greater likelihood to develop chemoresistance to frontline agents, but this was not statistically significant. Further studies with larger numbers of patients are needed to examine the relationship between autophagy activation and therapeutic outcome in ALL.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Anhänge
Nur mit Berechtigung zugänglich
Fußnoten
1
Cycle threshold (CT) or crossing point (Cp): The cycle at which the amplification plot crosses the threshold (i.e., there is a significant detectable increase in fluorescence).
 
Literatur
8.
11.
Zurück zum Zitat Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85:2025–37. CrossRef Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85:2025–37. CrossRef
15.
Zurück zum Zitat Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(‑Delta Delta C(T)) Method. Methods. 2001;25:402–8. CrossRef Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(‑Delta Delta C(T)) Method. Methods. 2001;25:402–8. CrossRef
22.
Zurück zum Zitat Lian Y, Xie Y, Hong M, Zhu Y, Zhao H, Zhao X, et al. Clinical significance of BECLIN1 and ATG5 expression in acute myeloid leukemia patients. Int J Clin Exp Pathol. 2018;11:1529–37. PubMedPubMedCentral Lian Y, Xie Y, Hong M, Zhu Y, Zhao H, Zhao X, et al. Clinical significance of BECLIN1 and ATG5 expression in acute myeloid leukemia patients. Int J Clin Exp Pathol. 2018;11:1529–37. PubMedPubMedCentral
23.
Metadaten
Titel
Value of autophagy-related gene 5 (ATG5) expression as a prognostic marker in adults with newly diagnosed acute lymphoblastic leukaemia (ALL)
verfasst von
Rasha I. Ibrahim
Haydi S. Mohamed
Mary G. Nagib
Hebatullah M. Fares
Alia M. Saeed
Publikationsdatum
18.06.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00715-3